As mimic cannabis medications become more and more commonplace for serious illnesses on the pharmaceutical market, lawmakers continue to limit and dismiss the medical potential of the cannabis plant.
Who Are Meda?
Meda is a registered trademark of Meda AB. Meda AB is located in Sweden. Cesamet and the Cesamet logo, however, are registered trademarks of Valeant Pharmaceuticals in North America.
Meda AB describes their vision as a global speciality pharmaceutical company with a focus on sustainable and profitable growth. They claim to provide quality products to their patients, shareholders, and other stakeholders. They pride themselves on their innovation and openness to different commercial models for prescription and non-prescription products. They seek to improve the well-being and quality of life of their patients and to uphold their international reputation.
Valeant Pharmaceuticals is also a multinational pharmaceutical and medical device company. They’re interested in developing and introducing state of the art, new treatments. Valeant’s corporate headquarters are in Laval, Quebec. Their U.S. headquarters, in charge of developing and commercializing Cesamet, are in Bridgewater, New Jersey. Valeant Pharmaceuticals is guided by five pillars that define their values: quality healthcare outcomes, [being] customer focused, efficiency, and people.
What Is Cesamet?
Cesamet is a specific type of antiemetic called a cannabinoid. Cannabinoids are medicines that focus on the endocannabinoid system. As a result, they are chemical formulations similar to those that are bodies already naturally produce. Cesamet is more specifically nabilone. The effects of nabilone are intended to mimic tetrahydrocannabinol (THC).
Cesamet was chemically engineered by a team of scientists to have similar ingredients, on a molecular level, as those found in marijuana. As it is a man-made, Meda is clear to explain, it is not medical marijuana. Cesamet is a registered FDA approved prescription medication. The medication is taken through oral administration.
Cesamet affects the central nervous system. It focuses on nerve cells in your brain, your stomach, and your abdomen that help cause nausea and vomiting. Nausea and vomiting occur as a bodily response to brain signals sent to your stomach and abdomen. The endocannabinoid system, easily targeted by cannabis and mimic drugs, impacts our overall nerves. This makes it so cannabinoids can address a range of ailments, such as pain, nausea, inflammation, skin health, etc.
Possible side effects of cesamet include drowsiness, a spinning sensation, dry mouth, feeling “high,” loss of coordination, headache, and difficulty concentrating. It can more concerningly cause mood shifts and hallucinations–auditory and visual.
Most concerningly, in some, cesamet can change heart rhythms. It can make your heart race or your blood pressure drop. According to Meda, It is not recommended to use cesamet if you have a history of abusing alcohol or marijuana. Prescriptions for cesamet hasn’t been studied in pregnant women or children, so it is not advised for them to take it until further studies take place.
If experiencing more common side effects of cesamet, when your doctor checks up on your progress, you should let them know. If your healthcare professionals know about the problem, they can address it. Talk to your doctor immediately, and ideally beforehand, if you have high blood pressure, heart concerns, or mental illness.
In the case of mental health, cesamet is one of the medicines that affect patients with depression, schizophrenia, bipolar disorder, and anxiety. As it is able to affect your mental state, cesamet may not be the right choice for those with mental illness.
What Is Cesamet For?
Cesamet is intended to relieve chemotherapy induced nausea and vomiting in cancer patients. Medicines that address CINV are all called antiemetics–including cesamet. Cesamet was approved by the FDA because it was found to help certain patients who have CINV.
During scientific trial, patients who took cesamet had three critical benefits over those who did not. They vomited less frequently, felt overall less nauseated, and were able to eat more post chemotherapy those who did not take cesamet. Patients who experienced these benefits did so as early as the first day of the trial. The progress also continued for these patients over the full five day study.